MCM
VERV

M28 Capital Management’s Verve Therapeutics VERV Stock Holding History

M28 Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-87,600
Closed -$3.01M – 16
2022
Q3 		$3.01M Sell
87,600
-90,900
-51% -$2.9M 3.14% 8
2022
Q2 		$2.73M Hold
178,500
– – 3.06% 10
2022
Q1 		$4.07M Buy
+178,500
New +$5.1M 3.74% 10

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

M28 Capital Management's VERV Position: Q4 2022 in Review

M28 Capital Management sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 87,600 shares — an estimated $3.01M sold.

M28 Capital Management first reported a position in VERV in Q1 2022 and held it in 3 quarters. The position peaked at $4.07M in Q1 2022. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

  • M28 Capital Management reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
  • M28 Capital Management sold 87,600 Verve Therapeutics shares in Q4 2022, an estimated $3.01M.
  • M28 Capital Management first reported a position in Verve Therapeutics in Q1 2022 and held it in 3 quarters.
  • M28 Capital Management's Verve Therapeutics position peaked at $4.07M in Q1 2022.
  • 123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on M28 Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.